Aggrenox Buyers Cry Foul In Pay-For-Delay Discovery Row
Three groups of purchasers alleging Boehringer Ingelheim paid Teva unit Barr Pharmaceuticals Inc. to keep a generic form of blood-clot medication Aggrenox off the market hit back at the drugmakers' discovery...To view the full article, register now.
Already a subscriber? Click here to view full article